Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients.

3036Background: Biomarkers may help to identify non-small cell lung cancer (NSCLC) patients (pts) more likely to have improved outcomes to anti-PD-L1 therapy. From 112 durvalumab (D)-treated pts, w...